Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

Clinical trial NCT05047185 · TERMINATED

Trial details

NCT number: NCT05047185
Sponsor: Pharvaris Netherlands B.V.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Hereditary Angioedema Hereditary Angioedema Type I Hereditary Angioedema Type II Hereditary Angioedema Types I and II Hereditary Angioedema Attack Hereditary Angioedema With C1 Esterase Inhibitor Deficiency Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 C1 Esterase Inhibitor Deficiency C1 Inhibitor Deficiency

Start date: 2022-04-19
Primary completion: 2025-06-30
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.